Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2012 Publisher: Novartis Pharmaceuticals UK Limited, Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR
CARDIOXANE 500mg, powder for solution for infusion.
| Pharmaceutical Form |
|---|
|
Powder for solution for infusion. Sterile, pyrogen free, white to off-white, lyophilised powder. |
Dexrazoxane 500.00mg as its hydrochloride salt.
For a vial of powder.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Dexrazoxane |
Dexrazoxane has two major mechanisms of action, chelation of iron and inhibition of topoisomerase II. It is not known to what extent each of these mechanisms contributes to the preventive effect on tissue destruction following anthracycline extravasation. |
| List of Excipients |
|---|
|
Not applicable. |
Vials (Type I brown glass), containing 500 mg of powder, closed with a chlorobutyl rubber stopper and an aluminium cap with pre-cut strip. The product is further enclosed in an outer carton. It is supplied in packs of 1 and 4 vials. Not all pack sizes may be marketed.
Novartis Pharmaceuticals UK Limited, Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR
PL 00101/0937
1 September 2006 / 16 February 2012
| Drug | Countries | |
|---|---|---|
| CARDIOXANE | Brazil, Ecuador, Spain, France, Hong Kong, Israel, Mexico, Netherlands, Poland, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
